A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2007-09-03
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 181
- Registration Number
- NCT00349284
- Locations
- 🇧🇪
Site 113, Charleroi, Belgium
🇧🇪Site 114, Dour, Belgium
🇧🇪Site 106, Genk, Belgium
Fenofibrate in Dyslipidemia and Metformin-Controlled Diabetes
Phase 2
Completed
- Conditions
- First Posted Date
- 2006-07-06
- Last Posted Date
- 2007-09-03
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 382
- Registration Number
- NCT00349128
- Locations
- 🇺🇦
Site 102, Kyiv, Ukraine
🇵🇱Site 201, Katowice, Poland
🇺🇦Site 112, Zaporizhya, Ukraine
Switch Study of Existing Atypical Antipsychotics to Bifeprunox
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-07-04
- Last Posted Date
- 2008-05-21
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 286
- Registration Number
- NCT00347425
- Locations
- 🇺🇸
Site 180, Kenilworth, New Jersey, United States
🇦🇷Site 308, Mendoza, Argentina
🇭🇺Site 212, Gyor, Hungary
Annual Study to Investigate Inactivated Subunit Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-06-30
- Last Posted Date
- 2009-01-30
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00346723
- Locations
- 🇧🇪
Site 1, Tessenderlo, Belgium
Annual Study to Investigate Inactivated Virosomal Influenza Vaccine for the 2006/2007 Influenza Season in Europe.
Phase 3
Withdrawn
- Conditions
- First Posted Date
- 2006-06-28
- Last Posted Date
- 2010-02-08
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 120
- Registration Number
- NCT00345462
- Locations
- 🇩🇪
Site 1, Berlin, Germany
An Open Label SLV308 Safety Extension to Study S308.3.003 in Early PD Patients
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2009-02-06
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 202
- Registration Number
- NCT00335374
- Locations
- 🇨🇳
389, Kaohsiung Hsien, Taiwan
🇨🇳387, Kaohsiung, Taiwan
🇵🇱368, Leszno, Poland
SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2008-04-03
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 330
- Registration Number
- NCT00335166
- Locations
- 🇺🇸
418, Albany, New York, United States
🇮🇳336, Mumbai, India
🇵🇱371, Kalisz, Poland
An Open Label SLV308 Safety Extension to Study S308.3.001 in Early PD Patients
- First Posted Date
- 2006-06-02
- Last Posted Date
- 2009-01-26
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 224
- Registration Number
- NCT00332917
- Locations
- 🇺🇸
Site 281, Pittsburgh, Pennsylvania, United States
🇨🇦Site 269, Saskatoon, Canada
🇦🇷Site 208, Capital Federal, CBA, Argentina
Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China
Phase 3
Completed
- Conditions
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 900
- Registration Number
- NCT00325260
- Locations
- 🇨🇳
Site 1, Nanjing, China
SLV308 for Treatment of Patients With Early Parkinson's Disease
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2008-08-29
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 468
- Registration Number
- NCT00269516
- Locations
- 🇧🇪
Site 100, Brussels, Belgium
🇧🇬Site 107, Plovdiv, Bulgaria
🇧🇬Site 104, Sofia, Bulgaria
© Copyright 2024. All Rights Reserved by MedPath